2023
Total and treatment-related costs of care associated with in patients with metastatic renal cell carcinoma receiving targeted or immune therapy.
Rahman S, Long J, Westvold S, Wheeler S, Spees L, Leapman M, Hurwitz M, McManus H, Gross C, Dinan M. Total and treatment-related costs of care associated with in patients with metastatic renal cell carcinoma receiving targeted or immune therapy. JCO Oncology Practice 2023, 19: 28-28. DOI: 10.1200/op.2023.19.11_suppl.28.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaOral anticancer agentsInitial treatmentRetrospective cohort studyUse of immunotherapyYear of diagnosisRenal cell carcinomaDirect treatment costsMean Medicare paymentsMedicare paymentsMedicare Part DInitial therapyCohort studyMetastatic diagnosisCell carcinomaCombination therapyImmunotherapyMedicare beneficiariesPatientsAge 65Disease controlOlder ageStudy periodTherapyDiagnosisRelative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US
Kc M, Fan J, Hyslop T, Hassan S, Cecchini M, Wang S, Silber A, Leapman M, Leeds I, Wheeler S, Spees L, Gross C, Lustberg M, Greenup R, Justice A, Oeffinger K, Dinan M. Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US. JAMA Network Open 2023, 6: e2323115. PMID: 37436746, PMCID: PMC10339147, DOI: 10.1001/jamanetworkopen.2023.23115.Peer-Reviewed Original ResearchConceptsLong-term survivorsCancer-specific mortalityColorectal cancerCancer cohortReceptor statusInitial diagnosisGleason scoreProstate cancerBreast cancerLong-term adult survivorsMedian cancer-specific survivalEnd Results cancer registryProstate-specific antigen levelRectal cancer cohortCancer-specific survivalStage III diseaseYear of diagnosisProgesterone receptor statusEstrogen receptor statusProportion of deathsSurvival time ratioEarly-stage cancerNononcologic outcomesIndex cancerLocalized disease
2020
Real-world systemic therapy utilization in Medicare patients with locally advanced or metastatic urothelial carcinoma diagnosed between 2008 and 2012
Dinan MA, Georgieva MV, Li Y, Zhang T, Harrison M, Shenolikar R, Scales CD. Real-world systemic therapy utilization in Medicare patients with locally advanced or metastatic urothelial carcinoma diagnosed between 2008 and 2012. Journal Of Geriatric Oncology 2020, 12: 298-304. PMID: 32912737, DOI: 10.1016/j.jgo.2020.08.005.Peer-Reviewed Original ResearchConceptsMetastatic urothelial carcinomaSecond-line chemotherapyUrothelial carcinomaOlder patientsSystemic therapyTreatment optionsMedicare patientsReal-world treatment patternsGrade IV diseaseAdvanced urothelial carcinomaSecond-line treatmentPoor oncologic outcomesYear of diagnosisUpper urinary tractLimited treatment optionsAcademic cancer centerSEER-Medicare dataForm of chemotherapyNon-academic centersDoublet chemotherapyPlatinum doubletsNeoadjuvant chemotherapyLine therapyOncologic outcomesRenal disease
2018
Survival Comparison in Patients with Stage IV Lung Cancer in Academic versus Community Centers in the United States
Ramalingam S, Dinan MA, Crawford J. Survival Comparison in Patients with Stage IV Lung Cancer in Academic versus Community Centers in the United States. Journal Of Thoracic Oncology 2018, 13: 1842-1850. PMID: 30312680, DOI: 10.1016/j.jtho.2018.09.007.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAdenocarcinoma of LungAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Large CellCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellCommunity Health CentersFemaleFollow-Up StudiesHumansLung NeoplasmsMaleMiddle AgedNeoplasm StagingRetrospective StudiesSurvival RateUnited StatesConceptsCommunity-based centersNational Cancer DatabaseSquamous cell carcinomaAcademic centersMetastatic NSCLCCell carcinomaLung cancerCancer DatabaseStage IV lung cancerSquamous cell lung cancerStage IV NSCLCPercentage of patientsYear of diagnosisCell lung cancerVariety of chemotherapyMultivariable regression modelsPrimary outcomeHistologic typeMultivariable analysisSignificant relative increasePrimary payerSurvival differencesSurvival comparisonsMultivariable modelTreatment strategiesAssociation between physician characteristics and the use of 21-gene recurrence score genomic testing among Medicare beneficiaries with early-stage breast cancer, 2008–2011
Wilson LE, Pollack CE, Greiner MA, Dinan MA. Association between physician characteristics and the use of 21-gene recurrence score genomic testing among Medicare beneficiaries with early-stage breast cancer, 2008–2011. Breast Cancer Research And Treatment 2018, 170: 361-371. PMID: 29536319, DOI: 10.1007/s10549-018-4746-6.Peer-Reviewed Original ResearchConceptsMedical oncologistsPhysician characteristicsBreast cancerGenomic testingMedicare beneficiariesAmerican Medical Association Physician Master FileNode-negative breast cancerEarly-stage breast cancerReceipt of testingMethodsRetrospective cohort studyYear of diagnosisPhysician-level factorsPhysician-level characteristicsMultivariable regression modelsAdjuvant chemotherapyCohort studyRS testingOptimal careResultsA totalStudy criteriaSurgical oncologySurgical proceduresHigher oddsMAIN OUTCOMELower oddsReal-world systemic therapy utilization in Medicare patients with locally advanced or metastatic urothelial carcinoma.
Dinan M, Georgieva M, Shenolikar R, Scales C. Real-world systemic therapy utilization in Medicare patients with locally advanced or metastatic urothelial carcinoma. Journal Of Clinical Oncology 2018, 36: 415-415. DOI: 10.1200/jco.2018.36.6_suppl.415.Peer-Reviewed Original ResearchMetastatic urothelial carcinomaMedicare patientsUrothelial carcinomaInitial chemotherapyPlatinum-doublet regimenAdvanced urothelial carcinomaDistant metastatic diseasePlatinum-containing chemotherapyReceipt of chemotherapyMetastatic bladder cancerYear of diagnosisCongestive heart failureGemcitabine/carboplatinGemcitabine/cisplatinUpper urinary tractCharacterized patientsDoublet chemotherapyNeoadjuvant chemotherapyDoublet regimenMetastatic diseaseMost patientsSystemic therapyHeart failureRenal diseaseComorbid conditions
2014
Redistribution of Health Care Costs after the Adoption of Positron Emission Tomography among Medicare Beneficiaries with Non–Small-Cell Lung Cancer, 1998–2005
Dinan MA, Curtis LH, Carpenter WR, Biddle AK, Abernethy AP, Patz EF, Schulman KA, Weinberger M. Redistribution of Health Care Costs after the Adoption of Positron Emission Tomography among Medicare Beneficiaries with Non–Small-Cell Lung Cancer, 1998–2005. Journal Of Thoracic Oncology 2014, 9: 512-518. PMID: 24736074, DOI: 10.1097/jto.0000000000000102.Peer-Reviewed Original ResearchConceptsCell lung cancerTotal health care costsHealth care costsPositron emission tomographyProportion of patientsRate of surgeryMedicare beneficiariesLung cancerCare costsEmission tomographySurgical resectionInpatient costsRetrospective cohort studyYear of diagnosisMain outcome measuresCohort studyTreatment patternsOutcome measuresRadiation therapyChemotherapyPatientsRadiotherapyStudy periodCancerMedicare approval
2010
Changes in the Use and Costs of Diagnostic Imaging Among Medicare Beneficiaries With Cancer, 1999-2006
Dinan MA, Curtis LH, Hammill BG, Patz EF, Abernethy AP, Shea AM, Schulman KA. Changes in the Use and Costs of Diagnostic Imaging Among Medicare Beneficiaries With Cancer, 1999-2006. JAMA 2010, 303: 1625-1631. PMID: 20424253, DOI: 10.1001/jama.2010.460.Peer-Reviewed Original ResearchConceptsNon-Hodgkin lymphomaLung cancerMedicare beneficiariesBreast cancerCancer typesColorectal cancerProstate cancerImaging costsPositron emission tomography scanIncident breast cancerYear of diagnosisEmission tomography scanBone density studiesMean total costMagnetic resonance imagingPositron emission tomographyBone scanTreatment patternsIncident casesCancer careHalf of beneficiariesTomography scanUS CentersMean annual increaseResonance imaging